Professor Norton and his team have developed a new therapeutic candidate for MS, called HsTX1[R14A]. This is an inhibitor that specifically shuts down activated “T cells”, including those that drive the attack on the brain and spinal cord in MS. It does this by potently blocking a specific “potassium channel”, which is only found on activated T cells. This compound represents a completely new class of drug for potential use in MS, and is a modified toxin from the venom of the scorpion, Heterometrus spinnifer.
With his collaborators, Professor Norton has demonstrated that this molecule is effective in laboratory models of MS. Other drugs in this class have recently been shown to be safe and effective in humans with another autoimmune disease, plaque psoriasis.
In this project, Professor Norton has teamed up with Associate Professor Natalie Trevakis, who is an expert in drug modification to improve persistence in the body. The team will modify the drug (by adding various lipids) and determine whether these modified versions have improved accumulation and persistence in the blood, the lymph nodes and the brain in a laboratory model.
If successful, this would pave the way for preclinical trials of a newly developed drug candidate for MS.
Updated 21 October 2020
Updated: 21 January, 2020
Laboratory research that investigates scientific theories behind the possible causes, disease progression, ways to diagnose and better treat MS.
Research that builds on fundamental scientific research to develop new therapies, medical procedures or diagnostics and advances it closer to the clinic.
Clinical research is the culmination of fundamental and translational research turning those research discoveries into treatments and interventions for people with MS.